{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T21:08:20Z","timestamp":1782248900687,"version":"3.54.5"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1097\/jcp.0b013e3181618eb4","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T06:33:54Z","timestamp":1236234834000},"page":"13-20","source":"Crossref","is-referenced-by-count":208,"title":["Aripiprazole Monotherapy in Nonpsychotic Bipolar I Depression"],"prefix":"10.1097","volume":"28","author":[{"given":"Michael E.","family":"Thase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arif","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"McQuade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald N.","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 5","key":"R1-3-20210128","first-page":"5","article-title":"The impact of bipolar depression.","volume":"66","author":"Post","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R2-3-20210128","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/archpsyc.59.6.530","article-title":"The long-term natural history of the weekly symptomatic status of bipolar I disorder.","volume":"59","author":"Judd","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"R3-3-20210128","doi-asserted-by":"crossref","first-page":"680","DOI":"10.4088\/JCP.v64n0610","article-title":"Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method.","volume":"64","author":"Post","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R4-3-20210128","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s11920-006-0055-6","article-title":"Pharmacotherapy of bipolar depression: an update.","volume":"8","author":"Thase","year":"2006","journal-title":"Curr Psychiatry Rep"},{"key":"R5-3-20210128","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.60.11.1079","article-title":"Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.","volume":"60","author":"Tohen","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R6-3-20210128","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1176\/appi.ajp.162.7.1351","article-title":"A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.","volume":"162","author":"Calabrese","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R7-3-20210128","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/01.jcp.0000248603.76231.b7","article-title":"Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).","volume":"26","author":"Thase","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"R8-3-20210128","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","article-title":"The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor.","volume":"441","author":"Jordan","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"R9-3-20210128","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.","volume":"302","author":"Burris","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"R10-3-20210128","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1124\/jpet.105.092155","article-title":"Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2\/D3 partial agonist.","volume":"315","author":"Burstein","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"R11-3-20210128","doi-asserted-by":"crossref","first-page":"626","DOI":"10.4088\/JCP.v67n0414","article-title":"A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder.","volume":"67","author":"Keck","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R12-3-20210128","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/0269881106059693","article-title":"Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study.","volume":"20","author":"Sachs","year":"2006","journal-title":"J Psychopharmacol"},{"key":"R13-3-20210128","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1176\/appi.ajp.160.9.1651","article-title":"A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania.","volume":"160","author":"Keck","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R14-3-20210128","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/10401230600801176","article-title":"Adjunctive aripiprazole in treatment-resistant bipolar depression.","volume":"18","author":"Ketter","year":"2006","journal-title":"Ann Clin Psychiatry"},{"key":"R15-3-20210128","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.pnpbp.2006.12.009","article-title":"Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia.","volume":"31","author":"Kemp","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R16-3-20210128","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jad.2006.11.025","article-title":"Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial.","volume":"101","author":"McElroy","year":"2007","journal-title":"J Affect Disord"},{"key":"R17-3-20210128","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.4088\/JCP.v66n1002","article-title":"Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder.","volume":"66","author":"Simon","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R18-3-20210128","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.4088\/JCP.v66n1017","article-title":"Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder.","volume":"66","author":"Papakostas","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R19-3-20210128","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4088\/PCC.v08n0205","article-title":"An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression.","volume":"8","author":"Patkar","year":"2006","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"R20-3-20210128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/10401230490521954","article-title":"Aripiprazole augmentation in treatment-resistant depression.","volume":"16","author":"Barbee","year":"2004","journal-title":"Ann Clin Psychiatry"},{"key":"R22-3-20210128","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00004850-200501000-00002","article-title":"3rd, Kinrys G, Wygant LE, et al. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients.","volume":"20","author":"Worthington","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"R23-3-20210128","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0920-9964(03)00050-1","article-title":"Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.","volume":"61","author":"Marder","year":"2003","journal-title":"Schizophr Res"},{"key":"R24-3-20210128","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.","volume":"63","author":"Kane","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R25-3-20210128","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4088\/JCP.v60n0203","article-title":"A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.","volume":"60","author":"Calabrese","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"R26-3-20210128","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","article-title":"Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.","volume":"60","author":"Potkin","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R27-3-20210128","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00004714-200004000-00012","article-title":"Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group.","volume":"20","author":"Muller-Oerlinghausen","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"R28-3-20210128","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0165-0327(80)90029-4","article-title":"A comparison of haloperidol, lithium carbonate and their combination in the treatment of mania.","volume":"2","author":"Garfinkel","year":"1980","journal-title":"J Affect Disord"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-200802000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:36:58Z","timestamp":1618277818000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-200802000-00003"}},"subtitle":["Results of 2 Randomized, Placebo-Controlled Studies"],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3181618eb4","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}